SML2928

Lumiracoxib

≥98% (HPLC)

• 동의어(들): 2-[(2-Chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid, 5-Methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid, CGS 35189, CGS-35189, CGS35189, COX 189, COX-189, COX189, LMX, Non-steroidal anti-inflammatory drug
• 실험식(Hill 표기법): C₁₅H₁₃ClFNO₂
• CAS Number: 220991-20-8
• Molecular Weight: 293.72
• MDL number: MFCD07186254
• UNSPSC 코드: 51111800
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to beige
• solubility: DMSO: 2 mg/mL, clear
• 저장 온도: 2-8°C
• SMILES string: ClC1=CC=CC(F)=C1NC2=CC=C(C)C=C2CC(O)=O
• InChI: 1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
• InChI key: KHPKQFYUPIUARC-UHFFFAOYSA-N

설명

생화학적/생리학적 작용

Lumiracoxib (COX189) is an orally active, potent and selective cyclooxygenase-2 inhibitor (K_i = 60 nM/COX-2 vs. 3.2 μM/COX-1) that inhibits COX-2-mediated PGE2 production in human whole blood (IC₅₀ = 130 nM; stimulation = 50 μM A23187), but not COX-1-dependent TxB2 production (IC₅₀ = 67 μM; stimulation = 10 μg/mL LPS). Lumiracoxib shows in vivo anti-inflammatory efficacy against carrageenan-induced paw oedema (ED₃₀ = 0.35 mg/kg p.o.), CFA-induced hyperalgesia (ED₃₀ = 5.1 mg/kg p.o.), as well as adjuvant-induced arthritis (ED₅₀ = 3 mg/kg/day p.o.) in rats in vivo.

Orally active, potent and selective cyclooxygenase-2 (COX-2) inhibitor with anti-inflammatory efficacy in vivo.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302
• 예방조치 성명서: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable